Late February Doldrums: A Week for Trading SMID Caps and Rebalancing…Update-2…sector watch biotech!
Update-2 2/24/26,,,Fears of AI disruption continues to dominate technology shares as traders move to so called -"HALO" stocks '-Heavy Assets Low Obsolescence", meaning avoid AI stocks find blue chip stocks free from software -things like Pepsi, GE and Exxon. Industrials (XLI) for example are up...
Wild Week of Rotation: Sector Performance 2026…Update-3… 2/12/26…the AI effect!
Update-3 2/15/26...More rotation ahead or waiting for Trump " State of the Nation?". Biotech stocks peaked on1/22 with the XBI at the $131 handle and now at $122.86. Here are current sector trends YTD: Leaders: Energy Materials Consumer Staples; Laggards: Financials, Information technology,...
Large Cap Biopharmaceuticals: A Core Position for a Healthcare Portfolio…Update-5…hot stock EVMN
Update-5 2/10...Evommune (EVMN) up over 70% to the $29 level on Ph.2 a proof of concept trial for moderate to severe atopic dermatitis. The Company completed an IPO at $16/sh in NOV. '25 for proceeds of $172M. REGN was down on the announcement but presented 36 abstracts at the AAAI Allergy...
Healthcare Sector Review: Biopharma and Genomics are Strong
Healthcare Sector Review January 2026 This should be a good time to set markers in anticipation of earnings and after a sell-off in health insurance stocks as well as severe re-balancing in Technology and Precious metals trade. So with technology stocks hit by Microsoft the IGV is down 12.7%...
Update to our Trading Model for SMID Biotech Stocks 2026…Update-5 UNH down on 2026 outlook and Medicare Plans
Update-5 1/27/27...The XLV was down 1.68% today primarily because UNH took \about a 20% hit on their 2026 outlook and proposed Medicare reimbursement from CMMS. Given the Administration's posture to cut healthcare costs this should not be a surprise. Moreover the XLV currently has only about a...